QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 27 December 2018SV NewsSV Health Investors listed 6th in Forbes list of VC's making the most investments in healthcare startups
- 1 June 2017Portfolio NewsBicycle Therapeutics Closes £40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline
- 27 April 2017Portfolio NewsArsanis Completes $45.5 Million Series D Financing
- 27 January 2017SV NewsKate Bingham receives BIA Lifetime Achievement Award at Annual Gala Dinner